Nuclear medicine applications in hemato-oncology

Turkish Journal of Haematology

Volumn 20, Issue 4, 2003, Pages 189-211

  Ilknur, A K ^a   Gülbaş, Zafer ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

67Ga; F 18 Fluorodeoxyglucose; Lymphoma; Multiple myeloma; Positron emission tomography; Tc 99m methoxy 2 isobutylisonitrile

Indexed keywords

ANGIOPEPTIN; ANTINEOPLASTIC AGENT; B LYMPHOCYTE ANTIBODY; BISMUTH 213; COLONY STIMULATING FACTOR; COLONY STIMULATING FACTOR 1; COPPER 67; DEPREOTIDE TC 99M; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; GLUCOSE; GLUCOSE TRANSPORTER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IMMUNOMODULATING AGENT; IODINE 123; IODINE 131; LAXATIVE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY; OCTREOTIDE; PENTETREOTIDE; RHENIUM 186; RITUXIMAB; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; STEROID; THALLIUM 201; UNINDEXED DRUG; VAPREOTIDE;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COST; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SYNTHESIS; DRUG TOXICITY; DRUG UPTAKE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; ISOTOPE LABELING; LAPAROTOMY; LIVER TOXICITY; LUNG TOXICITY; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; REVIEW; SCINTIGRAPHY; STEM CELL TRANSPLANTATION; STOMACH LYMPHOMA;

EID: 0347532766     PISSN: 13007777     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (164)

1. Ak I, Blokland JAK, Pauwels EKJ, Stokkel MPM. The clinical value of 18F-FDG detection with a dual-head coincidence camera: A review. Eur J Nucl Med 2001;28:763-78.
2. Warburg O. On the origin of cancer cells. Science 1956;235:1492-5.
3. Flier J, Mueckler M, Usher P, Lodish H. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987;235:1492-5.
4. Oheir P. Metabolism and transport of glucose and FDG. In: Ruhlman J, Oheir P, Biersack H (eds). PET in Oncology: Basic and Clinical Applications. Berlin Heidelberg: Springer, 1999:43-57.
5. Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, Yamada Y, Inoue K, Manabe T. Overexpression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990;170:223-30.
6. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-80.
7. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoural distribution of tritiated fluorodeoxyglucose in breast carcinoma: Are inflammatory cells important? J Nucl Med 1995;36:1854-61.
8. Yen RF, Chen ML, Liu FY, Ko SC, Chang YL, Chieng PU, Su CT. False-positive 2[F-18]-fluoro-2-deoxy-D-glucose positron emission tomography studies for evaluation of focal pulmonary abnormalities. J Formos Med Assoc 1998;79:642-5.
9. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987;28:288-92.
10. Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-hodgkin's lymphoma. J Nucl Med 1995;36:1790-6.
11. Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998;19:1055-63.
12. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, Kuyama J, Mikata A, Arimizu N. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity. J Nucl Med 1992;33:325-9.
13. Weder W, Schmid R, Bruchhaus H, Hillinger S, von Schulthess GK, Steinert HC. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998;66:886-93.
14. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 1999;213:530-6.
15. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, Kolokythas O, Herrmann F, Reske SN. Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997;203:795-800.
16. Hoh CK, Glaspy J, Rosen P, Dahlbom M, Lee SJ, Kunkel L, Hawkin RA, Maddahi J, Phelps ME. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997;38:343-8.
17. Moog F, Bangerter M, Diederichs C, Guhlmann A, Merkle E, Frickhofen N, Reske S. Extranodal malignant lymphoma: Detection with FDG PET versus CT. Radiology 1998;206:475-81.
18. Bangerter M, Moog F, Buchmann I, Kotzerke J, Griesshammer M, Hafner M, Elsner K, Frickhofen N, Reske SN, Bergmann L. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodking's disease. Ann Oncol 1998;9:721-8.
19. Stumpe K, Urbinelli M, Steinert H, Glanzmann C, Buck A, von Schulthess G. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721-8.
20. Jerusalem G, Beguin Y, Fassotte M, Najjar F, Paulus P, Rigo P, Fillet G. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429-33.
21. Tatsumi M, Kitayama H, Sugahara H, Tokita N, Nakamura H, Kanakura Y, Nishimura T. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma. J Nucl Med 2001;42:601-8.
22. Mikosch P, Gallowitsch HJ, Zinke-Cerwenka W, Heinisch M, Pipam W, Eibl M, Kresnik E, Unterweger O, Linkesch W, Lind P. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma. Acta Med Austriaca 2003;30:41-7.
23. Munker R, Stengel A, Stabler A, Hiller E, Brehm G. Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin's disease. Verification by laparotomy in 100 cases. Cancer 1995;76:1460-6.
24. Thill R, Neuerburg J, Fabry U, Cremerius U, Wagenknecht G, Hellwig D, Osieka R, Gunther R, Bull U. Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma. Nuklearmedizin 1997;36:234-49.
25. Shields AF, Porter BA, Churchley S, Olson DO, Appelbaum FR, Thomas ED. The detection of bone marrow involvement by lymphoma using magnetic resonance imaging. J Clin Oncol 1987;5:225-30.
26. Radford JA, Cowan RA, Flanagan M, Dunn G, Crowther D, Johnson RJ, Eddleston B. The significans of residual mediastinal abnormality on chest radiography following treatment for Hodgkin's disease. J Clin Oncol 1998;6:940-6.
27. Surbone A, Longo DL, DeVita VT JR, Ihde DC, Duffey PL, Jaffe ES, Dolomon D, Hubbard SM. Residual abdominal mass in agressive NHL after combination chemotherapy: Significance and management. J Clin Oncol 1988;6:1832-7.
28. Devizzi L, Maffoli L, Bonfante V, Vivani S, Balzarini L, Gasparini M, Valagussa P, Bomberdieri E. Comparison of gallium scan, CT and magnetic resonance in patients with mediastinal Hodgkin's disease. Annals of Oncol 1997;8:53-6.
29. Maisey NR, Hill ME, Webb A, Cunningham D, Flux GD, Padhani A, Ott RJ, Norman A, Bishop L. Are 18-fluorodeoxyglucose positron emission tomography and MRI imaging useful in the predicting of relaps in lymphoma residual masses? Eur J Cancer 2000;36:200-6.
30. Thomas F, Cosset JM, Cherel P, Renaudy N, Carde P, Piekarski JD. Thoracic CT: Scanning follow-up of residual mediastinal masses after treatment of Hodgkin's disease. Radiother Oncol 1988;11:119-22.
31. Zinzani PL, Magagnoli M, Chierichetti F, Zompatori M, Garraffa G, Bendandi M, Gherlinzoni F, Cellini C, Stefoni V, Ferlin G. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999;10:1181-94.
32. Maisey NR, Webb A, Flux GD, Padhani A, Cunningham DC, Ott RJ, Norman A. FDG-PET in the prediction of survival of patients with cancer of the pancreas: A pilot study. Br J Cancer 2000;83:287-93.
33. Cremerius U, Fabry U, Neuerburg J, Zimny M, Bares R, Osieka R, Bull U. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma. Nuklearmedizin 2001;40:23-30.
34. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1-93.
35. Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, Franke WG, Ehninger G. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001;115:793-800.
36. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G. Early restaging positron emission tomography with (18) F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1356-63.
37. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, Vanuytsel L, Bormans G, Balzarini J, De Wolf-Peeters C, Mortelmans L. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414-9.
38. Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 2003;30(Suppl 1):86-96.
39. Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003;44:224-39.
40. DeNardo GL, DeNardo SJ, Lamborn KR, Goldstein DS, Levy NB, Lewis JP, O'Grady L, Raventos A, Kroger LA, Macey DJ, McGahan JP, Mills SL, Shen S. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother Radiopharm 1998;13:239-54.
41. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993;34:773-9.
42. Lowe VJ. PET and radiotherapy. In: Ruhlmann J, Oehr P, Biersack H (eds). PET in Oncology: Basic and Clinical Application. Berlin: Springer-Verlag, 1999:189-94.
43. Romer W, Hanauske AR, Ziegler S, Thodtmann R, Weber W, Fuchs C, Enne W, Herz M, Nerl C, Garbrecht M, Schwaiger M. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464-71.
44. Torizuka T, Zasadny KR, Kison PV, Rommelfanger SG, Kaminski MS, Wahl RL. Metabolic response of non-Hodgkin's lymphoma to I-131-anti-B1 radioimmunotherapy: Evaluation with FDG PET. J Nucl Med 2000;41:999-1005.
45. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002;43:1018-27.
46. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000;85:613-8.
47. de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. F18-FDG PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001;12:29-37.
48. Coleman R. Camera-based PET: The best is yet to come. J Nucl Med 1997;38:1796-97.
49. Hwang K, Park C, Kim H, Yoon S, Pai M, Kim S. Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography. Clin Nucl Med 2000;25:789-95.
50. Pichler R, Maschek W, Hatzl-Griesenhofer M, Huber H, Wimmer G, Wahl G, Fridrik M. Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma-compared with conventional diagnostic methods. Nuklearmedizin 2000;39:166-73.
51. Ojha B, Bender LW, Francisco R, Scott JW. Recurrent lymphoma detected on F-18 FDG coincidence imaging with negative findings on Ga-67 citrate scintigraphy. Clin Nucl Med 2002;27:638-40.
52. Weinblatt ME, Zanzi I, Belakhlef A, Babchyck B, Kochen J. False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. J Nucl Med 1997;38:888-90.
53. Mayer D, Bednarczyk EM. Interaction of colony-stimulating factors and fluorodeoxyglucose F(18) positron emission tomography. Ann Pharmacother 2002;36:1796-9.
54. Schelbert HR, Hoh CK, Royal HD, Brown M, Dahlbom MN, Dehdashti F, Wahl RL. Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med 1998;39:1302-5.
55. Woolfenden JM, Pitto MJ, Durie BGM. Comparison of bone scintigraphy and radiography in multiple myeloma. Radiology 1980;134:726-31.
56. Van de Berg BC, Lecouvet FE, Michaux L, Labaisse M, Malghem J, Jamart J, Maldague BE, Ferrant A, Michaux JL. Stage I multiple myeloma: Value of MR imaging of the bone marrow in the determination of prognosis. Radiology 1996;201:243-6.
57. Kyle RA, Schreiman J, McLeod R. Computed tomography in diagnosis of multiple myeloma and its variants. Arch Intern Med 1985:145.
58. Yasuda S, Hoshikawa T, Yazawa N, Fukumitsu H, Ishikawa K, Suzuki T, Sadahiro S, Shimakura Y, Shibuya M, Nasu S, Tajima T, Makuuchi H. A case of duodenal involvement of multiple myeloma imaged by positron emission tomography with 18F-fluorodeoxyglucose. Tokai J Exp Clin Med 2001;26:147-51.
59. Jadvar H, Conti PS. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol 2002;31:690-4.
60. Durie BG, Waxman AD, D'Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 2002;43:1457-63.
61. Schirrmeister H, Bommer M, Buck AK, Muller S, Messer P, Bunjes D, Dohner H, Bergmann L, Reske SN. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002;39:361-6.
62. Orchard K, Barrington S, Buscombe J, Hilson A, Prentice HG, Mehta A. Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma. Br J Haematol 2002;117:133-5.
63. Tsan MF, Scheffel U. Mechanism of Ga-67 accumulation in tumours. J Nucl Med 1986;27:1215-9.
64. Hoffer P. Gallium: Mechanisms. J Nucl Med 1980;21:282-5.
65. Larson SM, Rasey JS, Allen DR, Nelson NJ. A transferrin-mediated uptake of Ga-67 by EMT-6 sarcoma. I. Studies in tissue culture. J Nucl Med 1979;20:837-42.
66. Kriegel H. Biokinetics and metabolism of radiogallium. Nuklearmedizin 1984;23:53-7.
67. Tzen KY, Oster ZH, Wagner HN Jr, Tsan MF. Role of iron-binding proteins and enhanced capillary permeability on the accumulation of gallium-67. J Nucl Med 1980;21:31-5.
68. Weiner R, Hoffer PB, Thakur ML. Lactoferrin: Its role as a Ga-67-binding protein in polymorphonuclear leukocytes. J Nucl Med 1981;22:32-7.
69. Neilands JB. Microbial envelope proteins related to iron. Annu Rev Microbiol 1982;36:285-305.
70. Ando A, Nitta K, Ando I, Sanada S, Katsuda S, Tonami N, Hirak IT, Hisada K, Ogawa H. Mechanism of gallium 67 accumulation in inflammatory tissue. Eur J Nucl Med 1990;17:21-7.
71. Peylan-Ramu N, Haddy TB, Jones E, Horvath K, Adde MA, Magrath IT. High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma. J Clin Oncol 1989;7:1800-6.
72. Luker GD, Siegel MJ. Mediastinal Hodgkin disease in children: Response to therapy. Radiology 1993;189:737-40.
73. Engelstad B, Luk SS, Hattner RS. Altered 67Ga citrate distribution in patients with multiple red blood cell transfusions. AJR Am J Roentgenol 1982;139:755-9.
74. Bekerman C, Pavel DG, Bitran J, Ryo UY, Pinsky S. The effects of inadvertent administration of antineoplastic agents prior to Ga-67 injection: Concise communication. J Nucl Med 1984;25:430-5.
75. Anderson KC, Leonard RC, Canellos GP, Skarin AT, Kaplan WD. High-dose gallium imaging in lymphoma. Am J Med 1983;75:327-31.
76. Jochelson MS, Herman TS, Stomper PC, Mauch PM, Kaplan WD. Planning mantle radiation therapy in patients with Hodgkin disease: Role of gallium-67 scintigraphy. AJR Am J Roentgenol 1988;151:1229-31.
77. Stomper PC, Cholewinski SP, Park J, Bakshi SP, Barcos MP. Abdominal staging of thoracic Hodgkin disease: CT-lymphagiography-Ga-67 scanning correlation. Radiology 1993;187:381-6.
78. Larcos G, Farlow DC, Antico VF, Gruenewald SM, Boyages J. The role of high dose 67-gallium scintigraphy in staging untreated patients with lymphoma. Aust N Z J Med 1994;24:5-8.
79. Ak I, Gülbaş Z, Seyman N, Vardareli E. Hodgkin ve non-hodgkin lenfomada Ga-67'nin tanisal deǧeri (abstract). Turk J Nucl Med 1997;6:69.
80. Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 flurodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002;94:879-88.
81. Tumeh SS, Rosenthal DS, Kaplan WD, English RJ, Holman BL. Lymphoma: Evaluation with Ga-67 SPECT. Radiology 1987;164:111-4.
82. Front D, Israel O. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin Nucl Med 1995;25:60-71.
83. Ben-Haim S, Bar-Shalom R, Srael O, Haim N, Epelbaum R, Ben-Shachar M, Gaitini D, Kolodny GM, Front D. Utility of gallium-67 scintigraphy in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1996;14:1936-42.
84. Sandrock D, Lastoria S, Magrath IT, Neumann RD. The role of gallium-67 tumour scintigraphy in patients with small, non-cleaved cell lymphoma. Eur J Nucl Med 1993;20:119-22.
85. Rehm PK. Radionuclide evaluation of patients with lymphoma. Radiol Clin North Am 2001;39:957-78.
86. Gasparini MD, Balzarini L, Castellani MR, Tesoro Tess JD, Maffioli LS, Petrillo R, Ceglia E, Musumeci R, Buraggi GL. Current role of gallium scan and magnetic resonance imaging in the management of mediastinal Hodgkin lymphoma. Cancer 1993;72:577-82.
87. Hill M, Cunningham D, MacVicar D, Roldan A, Husband J, McCready R, Mansi J, Milan S, Hickish T. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol 1993;11:2273-8.
88. Zinzani PL, Zompatori M, Bendandi M, Battista G, Fanti S, Barbieri E, Gherlinzon IF, Rimondi MR, Frezza G, Pisi P, Merla E. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1996;22:131-5.
89. Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997;15:1631-7.
90. Ionescu I, Brice P, Simon D, Guermazi A, Leblanc T, Rousselot P, Gossot D, Meignin V, Gisselbrecht C, Rain JD. Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients. Med Oncol 2000;17:127-34.
91. Ha CS, Choe JG, Kong JS, Allen PK, Oh YK, Cox JD, Edmund E. Agreement rates among single photon emission computed tomography using gallium-67, computed axial tomography and lymphagiography for Hodgkin disease and correlation of image findings with clinical outcome. Cancer 2000;89:1371-9.
92. King SC, Reiman RJ, Prosnitz LR. Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease. J Clin Oncol 1994;12:306-11.
93. Israel O, Mor M, Epelbaum R, Frenkel A, Haim N, Dann EJ, Gaitini D, Bar-Shalom R, Kolodny GM, Front D. Clinical pretreatment risk factors and Ga-67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non-Hodgkin lymphoma. Cancer 2002;94:873-8.
94. Hsu CH, Sun SS, Kao CH, Lin CC, Lee CC. Differentiation of low-grade gastric MALT lymphoma and high-grade gastric MALT lymphoma: The clinical value of Ga-67 citrate scintigraphy - A pilot study. Cancer Invest 2002;20:939-43.
95. Bar-Shalom R, Mor M, Yefremov N, Goldsmith SJ. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment. Semin Nucl Med 2001;31:117-90.
96. Wirth A, Seymour JF, Hicks RJ, Ware R, Fisher R, Prince M, MacManus MP, Ryan G, Januszewicz H, Wolf M. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002;112:262-8.
97. Rini JN, Manalili EY, Hoffman MA, Karayalcin G, Mehrotra B, Tomas MB, Palestro CJ. F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease. Clin Nucl Med 2002;27:572-8.
98. Shen YY, Kao A, Yen RF. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Oncol Rep 2002;9:321-5.
99. Delmon-Moingeon L, Piwnica-Worms D, Van Den Abbee A, Holman L, Davidson A, Jones A. Uptake of cation hexakis (2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell line in vitro. Cancer Res 1990;50:2198-202.
100. Chiu M, Kronauge J, Piwnika-Worms D. Effect of mitocondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile)-technetium (I) in cultured mouse fibroblast. J Nucl Med 1990;31:1646-53.
101. Carvalho PA, Chiu ML, Kronauge JF, Kawamura M, Jones AG, Holman BL, Piwnica-Worms D. Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med 1992;33:1516-22.
102. Piwnica-Worms D, Kronauge J, Chiu M. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium (I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990;82:1826-38.
103. Piwnica-Worms D, Chiu M, Budding M, Kronauge J, Kramer R, Croop J. Functional imaging of multidrug resistant p-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-84.
104. Ballinger JR, Hua HA, Berry BW, Firby P, Boxen I. 99Tcm-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: In vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl Med Commun 1995;16:253-7.
105. Müller ST, Guth-Tougelides B, Creutzig H. Imaging of malignant tumours with Tc99m MIBI (abstract). J Nucl Med 1987;28:562.
106. Wilczek B, Aspelin P, Bone B, Pegerfalk A, Frisell J, Danielsson R. Complementary use of scintimammography with 99m-tc-MIBI to triple diagnostic procedure in palpable and non-palpable breast lesions. Acta Radiol 2003;44:288-93.
107. Ak I, Gulbas Z, Altinel F, Vardareli E. Tc-99m MIBI uptake and its relation to the proliferative potential of brain tumors. Clin Nucl Med 2003;28:29-33.
108. Hsu CH, Liu FY, Yen RF, Kao CH. Tc-99m MIBI SPECT in detecting metastatic papillary thyroid carcinoma in patients with elevated human serum thyroglobulin levels but negative I-131 whole body scan. Endocr Res 2003;29:9-15.
109. Moustafa H, Riad R, Omar W, Zaher A, Ebied E. 99mTc-MIBI in the assessment of response to chemotherapy and detection of recurrences in bone and soft tissue tumours of the extremities. Q J Nucl Med 2003;47:51-7.
110. Alexandrakis MG, Kyriakou DS, Passam FH, Malliaraki N, Christophoridou AV, Karkavitsas N. Correlation between the uptake of Tc-99m-sestaMIBI and prognostic factors in patients with multiple myeloma. Clin Lab Haematol 2002;24:155-9.
111. Teodori E, Dei S, Scapecchi S, Gualtieri F. The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco 2002;57:385-415.
112. Bradshaw DM, Arceci RC. Clinical relevance of transmembrane drug efflux as a multidrug resistance. J Clin Oncol 1998;16:3674-90.
113. Ciarmiello A, Del Vecchio S, Silvestro P, Potena MI, Carriero MV, Mainolfi C, Botti G, Thomas R, D'Aiuto G, Salvatore M. Tumour clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998;16:1677-83.
114. Del Vecchio S, Zannetti A, Ciarmiello A, Aloj L, Caraco C, Fonti R, Botti G, D'Aiuto G, Salvatore M. Dynamic coupling of (99m)Tc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients. Eur J Nucl Med Mol Imaging 2002;29:809-14.
115. Cordobes MD, Starzec A, Delmon-Moingeon L, Blanchot C, Kouyoumdjian JC, Prevost G, Caglar M, Moretti JL. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: Correlation with mdr gene expression. J Nucl Med 1996;37:286-9.
116. Kostakoglu L, Ruacan S, Ergun EL, Sayek I, Elahi N, Bekdik CF. Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer. J Nucl Med 1998;39:228-34.
117. Kostakoglu L, Kiratli P, Ruacan S, Hayran M, Emri S, Ergun EL, Bekdik CF. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med 1998;39:228-34.
118. Burak Z, Ersoy O, Moretti JL, Erinc R, Ozcan Z, Dirlik A, Sabah D, Basdemir G. The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: Comparison with therapy response. Eur J Nucl Med 2001;28:1341-50.
119. Wood P, Burgess R, MacGregor A, Yin JA. P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 1994;87:509-14.
120. Kostakoglu L, Guc D, Canpinar H, Kars A, Alper E, Kiratli P, Hayran M, Gunduz U, Kansu E. P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy. J Nucl Med 1998;39:1191-7.
121. Gruber A, Arestrom I, Xu D, Liliemark J, Larsson SA, Jacobsson H. Multidrug resistance phenotype in leukaemic cells from patients with acute myelocytic leukaemia can be detected with 99Tc(m)-MIBI. Br J Cancer 1998;77:1732-6.
122. Ak I, Aslan V, Vardareli E, Gulbas Z. Assessment of the P-glycoprotein expression by 99mTc-MIBI bone marrow imaging in patients with untreated leukaemia. Nucl Med Commun 2003;24:397-402.
123. Fonti R, Del Vecchio S, Zannetti A, De Renzo A, Di Gennaro F, Catalano L, Califano C, Pace L, Rotoli B, Salvatore M. Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma. Eur J Nucl Med 2001;28:214-20.
124. Ak I, Aslan V, Vardareli E, Gulbas Z. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: Correlation with CD38/CD138 expressing myeloma cells. Ann Hematol 2003;82:88-92.
125. Pace L, Catalano L, Pinto A, De Renzo A, Di Gennaro F, Califano C, Del Vecchio S, Rotoli B, Salvatore M. Different patterns of technetium-99m sestamibi uptake in multiple myeloma. Eur J Nucl Med 1998;25:714-20.
126. Catalano L, Pace L, Califano C, Pinto A, De Renzo A, Di Gennaro F, Del Vecchio S, Fonti R, Salvatore M, Rotoli B. Detection of myeloma lesions by technetium-99m-sestaMIBI scintigraphy. Haematologica 1999;84:119-24.
127. Alexandrakis MG, Kyriakou DS, Passam F, Koukouraki S, Karkavitsas N. Value of Tc-99m sestamibi scintigraphy in the detection of bone lesions in multiple myeloma: Comparison with Tc-99m methylene diphosphonate. Ann Hematol 2001 2001;80:349-53.
128. Svaldi M, Tappa C, Gebert U, Bettin ID, Fabris P, Franzelin F, Osele L, Mitterer M. Technetium-99m-sestamibi scintigraphy: An alternative approach for diagnosis and follow-up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation. Ann Hematol 2001;80:393-7.
129. Alper E, Gurel M, Evrensel T, Ozkocaman V, Akbunar T, Demiray M. 99mTc-MIBI scintigraphy in untreated stage III multiple myeloma: Comparison with X-ray skeletal survey and bone scintigraphy. Nucl Med Commun 2003;24:537-42.
130. Patel YC, Greenwood MT, Warszynska A, Panetta R, Srikant CB. All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase. Biochem Biophys Res Commun 1994;198:605-12.
131. Scarpignato C, Pelosini I. Somatostatin analogues for cancer treatment and diagnosis: An overview. Chemotherapy 2001;47:1-29.
132. Kwekkeboom D, Krenning EP, De Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000;41:1704-13.
133. Lamberts SW, Koper JW, Reubi JC. Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest 1987;17:354-9.
134. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ. SMS 2001-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133-40.
135. Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooij PP, Reubi JC, Klijn JG, Visser TJ, Docter R, Lamberts SW. Receptor scintigraphy with a radioiodinated somatostatin analogue: Radiolabelling, purification, biologic activity, and in vivo application in animals. J Nucl Med 1990;31:1501-9.
136. Bruns C, Raulf F, Hoyer D, Schloos J, Lubbert H, Weckbecker G. Binding properties of somatostatin receptor subtypes. Metabolism 1996;45:17-20.
137. Lugtenburg PJ, Krenning EP, Valkema R, Oei HY, Lamberts SW, Eijkemans MJ, Van Putten WL, Lowenberg B. Somatostatin receptor scintigraphy useful in stage I-II Hodgkin's disease: More extended disease identified. Br J Haematol 2001;112:936-44.
138. Lugtenburg PJ, Lowenberg B, Valkema R, Oei HY, Lamberts SW, Eijkemans MJ, Van Putten WL, Krenning EP. Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas. J Nucl Med 2001;42:222-9.
139. Mandigers CM, Raemaekers JM, Schattenberg AV, Roovers EA, Bogman MJ, Van Der Maazen RW, De Pauw BE, De Witte T. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma. Br J Haematol 1998;100:198-206.
140. Ma D, McDevitt MR, Barendswaard E, Lai L, Curcio MJ, Pellegrini V, Brechbiel MW, Scheinberg DA. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia 2002;16:60-6.
141. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262-9.
142. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63.
143. Tuscano JM, O'Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, Tedder TF, DeNardo GL. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. Blood 2003;1:3641-7.
144. Buchsbaum DJ, Wahl RL, Normolle DP, Kaminski MS. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 1992;52:6476-81.
145. Reff ME, Carner K, Chambers KS, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
146. Ottonello L, Morone P, Dapino P, Dallegri F. Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokinine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes. Blood 1996;87:5171-8.
147. Juweid M, Sharkey RM, Goldenberg DM. Radioimmunotherapy of non-Hodgkin's lymphoma with non-myeloablative doses of radiolabeled monoclonal antibodies. In: Riva P (ed). Therapy of Malignancies with Radioconjugate Monoclonal Antibodies: Present Possibilities and Future Perspectives. Philadelphia: Harwood Academic Publisher, 1999: 245-62.
148. DeNardo SJ, DeNardo GL, O'Grady LF, Macey DJ, Mills SL, Epstein AL, Peng JS, McGahan JP. Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers 1987;2:49-53.
149. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793-803.
150. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: From clinical trials to clinical practise. J Nucl Med 2002;43:1507-29.
151. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-65.
152. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974-81.
153. Vose JM, Colcher D, Gobar L, Bierman PJ, Augustine S, Tempero M, Leichner P, Lynch JC, Goldenberg D, Armitage JO. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leuk Lymphoma 2000;38:91-101.
154. DeNardo GL. The next generation of imaging and therapeutic agents for lymphoma and chronic lymphocytic leukemia. New Perspect Cancer Diagn Manage 1995;3:76-83.
155. O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Carr CE, Mirick GR, DeNardo SJ. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med 1999;40:2014-20.
156. O'Donnell RT, DeNardo DL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Mirick GR. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma. Clin Cancer Res 1999;5:3330-6.
157. McDevitt MR, Sgouros G, Finn RD, Human JL, Jurcic JG, Larson SM, Scheinberg DA. Radioimmunotherapy with alpha emitting nuclides. Eur J Nucl Med 1998;25:1341-51.
158. Jurcic JG. Antibody therapy of acute myelogenous leukemia. Cancer Biother Radiopharm 2000;15:319-26.
159. Wagner HN Jr, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-Bennett DM, Lamonica DM, Conti PS. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90) Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2002;43:267-72.
160. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-24.
161. Juweid M, Sharkey RM, Markowitz A, Behr T, Swayne LC, Dunn R, Hansen HJ, Shevitz J, Leung SO, Rubin AD. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 1995;55:5899-907.
162. Krasner C, Joyce RM. Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma. Curr Pharm Biotechnol 2001;24:341-9.
163. Wiseman GA, Leigh B, Erwin WD, Lamonica D, Kornmehl E, Spies SM, Silverman DH, Witzig TE, Sparks RB, White CA. Radiation dosimetry results for zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 2002;15:1349-57.
164. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Brown S, Nelp WB, Krohn KA. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 1989;7:1027-38.